What is a stock summary page? Click here for an overview.
Business Description
Kyorin Pharmaceutical Co Ltd
NAICS : 325411
SIC : 2833
ISIN : JP3247090008
Description
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 2.82 | |||||
| Interest Coverage | 71.57 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.47 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.1 | |||||
| 3-Year EBITDA Growth Rate | -1.8 | |||||
| 3-Year EPS without NRI Growth Rate | 1.3 | |||||
| 3-Year Book Growth Rate | 1.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 3.83 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2.58 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.11 | |||||
| 9-Day RSI | 54.75 | |||||
| 14-Day RSI | 50.94 | |||||
| 3-1 Month Momentum % | 11.11 | |||||
| 6-1 Month Momentum % | 5.54 | |||||
| 12-1 Month Momentum % | -10.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.58 | |||||
| Quick Ratio | 1.74 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 293.27 | |||||
| Days Sales Outstanding | 127.38 | |||||
| Days Payable | 75.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.52 | |||||
| Dividend Payout Ratio | 0.58 | |||||
| 3-Year Dividend Growth Rate | -11.5 | |||||
| Forward Dividend Yield % | 4.34 | |||||
| 5-Year Yield-on-Cost % | 2.2 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 2.19 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.71 | |||||
| Operating Margin % | 5.2 | |||||
| Net Margin % | 3.92 | |||||
| FCF Margin % | -3.92 | |||||
| ROE % | 3.65 | |||||
| ROA % | 2.63 | |||||
| ROIC % | 3.18 | |||||
| 3-Year ROIIC % | 1.6 | |||||
| ROC (Joel Greenblatt) % | 6.14 | |||||
| ROCE % | 4.68 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.09 | |||||
| Forward PE Ratio | 16.57 | |||||
| PE Ratio without NRI | 16.41 | |||||
| Shiller PE Ratio | 12.66 | |||||
| PS Ratio | 0.71 | |||||
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| Price-to-Operating-Cash-Flow | 54.68 | |||||
| EV-to-EBIT | 14.75 | |||||
| EV-to-EBITDA | 10.86 | |||||
| EV-to-Revenue | 0.79 | |||||
| EV-to-FCF | -20.21 | |||||
| Price-to-GF-Value | 0.75 | |||||
| Price-to-Projected-FCF | 0.82 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Graham-Number | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Earnings Yield (Greenblatt) % | 6.78 | |||||
| FCF Yield % | -5.54 | |||||
| Forward Rate of Return (Yacktman) % | -2.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kyorin Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 119,734 | ||
| EPS (TTM) (円) | 81.6 | ||
| Beta | 0.13 | ||
| 3-Year Sharpe Ratio | -0.36 | ||
| 3-Year Sortino Ratio | -0.46 | ||
| Volatility % | 18.24 | ||
| 14-Day RSI | 50.94 | ||
| 14-Day ATR (円) | 36.786913 | ||
| 20-Day SMA (円) | 1471.65 | ||
| 12-1 Month Momentum % | -10.81 | ||
| 52-Week Range (円) | 1331 - 1843 | ||
| Shares Outstanding (Mil) | 57.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kyorin Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kyorin Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kyorin Pharmaceutical Co Ltd Frequently Asked Questions
What is Kyorin Pharmaceutical Co Ltd(TSE:4569)'s stock price today?
The current price of TSE:4569 is 円1476.00. The 52 week high of TSE:4569 is 円1843.00 and 52 week low is 円1331.00.
When is next earnings date of Kyorin Pharmaceutical Co Ltd(TSE:4569)?
The next earnings date of Kyorin Pharmaceutical Co Ltd(TSE:4569) is .
Does Kyorin Pharmaceutical Co Ltd(TSE:4569) pay dividends? If so, how much?
The Dividend Yield %  of Kyorin Pharmaceutical Co Ltd(TSE:4569) is 3.52% (As of Today), Highest Dividend Payout Ratio of Kyorin Pharmaceutical Co Ltd(TSE:4569) was 0.91. The lowest was 0.3. And the median was 0.67. The  Forward Dividend Yield % of Kyorin Pharmaceutical Co Ltd(TSE:4569) is 4.34%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers